

# Video NeuroImages: Idiopathic Recurring Stupor

## An Unusual Clinical Condition Responding to Flumazenil

Andrea Gómez García, MD, Inmaculada Navas Vinagre, MD, and Antonio Herranz Bárcenas, MD

*Neurology*® 2021;96:586. doi:10.1212/WNL.0000000000011548

### Correspondence

Dr. Gómez García  
andreaagomez1703@  
gmail.com

### MORE ONLINE

#### ▶ Video

#### → Teaching slides

[links.lww.com/WNL/  
B325](https://links.lww.com/WNL/B325)

A 73-year-old woman presented with a history of recurrent self-limited stupor episodes. Metabolic, vascular, structural, epileptic, toxicologic (exogenous), and sleep disorders were excluded after the pertinent investigations. We present video-EEG results during one of the episodes (video 1).

Idiopathic recurring stupor is an uncommon and controversial condition, with diagnosis requiring exclusion of a variety of other causes of stupor and supported by the detection of elevated levels of endozepine-4 in serum and CSF during episodes.<sup>1,2</sup> In the right clinical context, characteristic EEG pre and post administration of flumazenil and clinical response to this drug can be suggestive.

### Study Funding

No targeted funding reported.

### Disclosure

The authors report no disclosures relevant to the manuscript. Go to [Neurology.org/N](https://Neurology.org/N) for full disclosures.

### Appendix Authors

Name	Location	Contribution
<b>Andrea Gómez García, MD</b>	Department of Neurology, Fundación Jiménez Díaz, Madrid, Spain	Data recompilation, clinical review, manuscript edition
<b>Inmaculada Navas Vinagre, MD</b>	Department of Neurology, Fundación Jiménez Díaz, Madrid, Spain	Manuscript review, data recompilation
<b>Antonio Herranz Bárcenas, MD</b>	Department of Neurology, Fundación Jiménez Díaz, Madrid, Spain	Manuscript review, data recompilation, video edition

### References

1. Granot R, Berkovik SF, Patterson S, et al. Idiopathic recurrent stupor: a warning. *J Neurol Neurosurg Psychiatry* 2004;75:368–369.
2. Cortelli P, Avallone R, Baraldi M, et al. Endozepines in recurrent stupor. *Sleep Med Rev* 2005;9:477–487.

From the Department of Neurology, Fundación Jiménez Díaz, Madrid, Spain.

Go to [Neurology.org/N](https://Neurology.org/N) for full disclosures.

# Neurology®

## Video NeuroImages: Idiopathic Recurring Stupor: An Unusual Clinical Condition Responding to Flumazenil

Andrea Gómez García, Inmaculada Navas Vinagre and Antonio Herranz Bárcenas  
*Neurology* 2021;96;586 Published Online before print January 13, 2021  
DOI 10.1212/WNL.0000000000011548

**This information is current as of January 13, 2021**

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://n.neurology.org/content/96/12/586.full">http://n.neurology.org/content/96/12/586.full</a>
<b>References</b>	This article cites 2 articles, 1 of which you can access for free at: <a href="http://n.neurology.org/content/96/12/586.full#ref-list-1">http://n.neurology.org/content/96/12/586.full#ref-list-1</a>
<b>Citations</b>	This article has been cited by 1 HighWire-hosted articles: <a href="http://n.neurology.org/content/96/12/586.full##otherarticles">http://n.neurology.org/content/96/12/586.full##otherarticles</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>All Clinical Neurology</b> <a href="http://n.neurology.org/cgi/collection/all_clinical_neurology">http://n.neurology.org/cgi/collection/all_clinical_neurology</a> <b>All Sleep Disorders</b> <a href="http://n.neurology.org/cgi/collection/all_sleep_disorders">http://n.neurology.org/cgi/collection/all_sleep_disorders</a> <b>EEG</b> <a href="http://n.neurology.org/cgi/collection/eeg_">http://n.neurology.org/cgi/collection/eeg_</a> <b>Other hypersomnias</b> <a href="http://n.neurology.org/cgi/collection/other_hypersomnias">http://n.neurology.org/cgi/collection/other_hypersomnias</a>
<b>Errata</b>	An erratum has been published regarding this article. Please see <a href="#">next page</a> or: <a href="/content/97/14/704.2.full.pdf">/content/97/14/704.2.full.pdf</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2021 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.



## Video NeuroImages: Idiopathic Recurring Stupor

An Unusual Clinical Condition Responding to Flumazenil

*Neurology*® 2021;97:704. doi:10.1212/WNL.0000000000012132

In the article “Video NeuroImages: Idiopathic Recurring Stupor: An Unusual Clinical Condition Responding to Flumazenil” by Gómez García et al.,<sup>1</sup> there were errors regarding the article type and its title. The article should have been published in the Video NeuroImages section, and the correct title is “Idiopathic Recurring Stupor: An Unusual Clinical Condition Responding to Flumazenil.” In addition, there are no Teaching Slides with this article. The publisher regrets the errors.

### Reference

1. Gómez García A, Navas Vinagre J, Herranz Bárcenas A. Video NeuroImages: Idiopathic recurring stupor: an unusual clinical condition responding to flumazenil. *Neurology*. 2021;96(12):586.

## AAN’s First 21st-Century Position Statement on Ethical Consideration in Dementia Diagnosis and Care

*Neurology*® 2021;97:704. doi:10.1212/WNL.0000000000012606

The Editor retracts this editorial<sup>1</sup> at the request of the author because the author's views on the topic are no longer reflected in the editorial in light of the FDA's approval of the drug aducanumab for use in treatment of Alzheimer disease. The FDA approved the drug on June 7, 2021, after the editorial was submitted (February 25, 2021) or accepted in final form by *Neurology* (March 4, 2021) but before it was published (July 13, 2021).

### Reference

1. Boylan LS. AAN's first 21st-century position statement on ethical consideration in dementia diagnosis and care. *Neurology*. 2021;97(2):57-58.